Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD
Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine whether treatment with Armodafinil
(CEP-10953) is more effective than placebo treatment for patients with excessive sleepiness
associated with chronic shift work sleep disorder (SWSD) by measuring mean sleep latency from
the Multiple Sleep Latency Test (MSLT) (20 minutes) (average of 4 naps at 0200, 0400, 0600,
and 0800) and by Clinical Global Impression of Change (CGI-C) ratings.